Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Last trade$69.60
Day change-$0.22 (-0.32%)
Day range$68.64 – $70.91
Volume125,331
Market cap$2.08B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.08B
Price / earnings
—
Price / book
133.53×
Price / sales
7.89×
EV / sales
8.61×
EV / EBITDA
-301.87×
Profitability
Earnings per share
-$1.29
Return on assets
-10.72%
Return on equity
-246.59%
Dividend yield
0%
Liquidity and leverage
Debt / equity
17.17×
Current ratio
3.57×
Quick ratio
2.38×
Cash ratio
1.06×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.6M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ESTA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$71.99M
$67.54M
$59.88M
$64.62M
$53.78M
$51.3M
$41.38M
$44.51M
Cost of revenue
$22.28M
$19.83M
$17.54M
$19.09M
$16.09M
$16.03M
$13.57M
$14.02M
Gross profit
$49.71M
$47.71M
$42.34M
$45.53M
$37.7M
$35.27M
$27.81M
$30.49M
Selling, general and administrative
$48.02M
$46.91M
$43.61M
$44.03M
$37.17M
$44.18M
$39.7M
$44.02M
Research and development
$4.31M
$5.1M
$5.24M
$5.43M
$4.56M
$5.2M
$5.06M
$5.14M
Total operating expenses
$52.34M
$52M
$48.85M
$49.46M
$41.72M
$49.38M
$44.75M
$49.16M
Operating income
-$2.62M
-$4.29M
-$6.51M
-$3.93M
-$4.03M
-$14.11M
-$16.95M
-$18.67M
Interest expense
-$6.81M
-$7.03M
-$7.09M
-$7.24M
-$6.2M
-$5.96M
-$5.85M
-$5.95M
Income before taxes
-$10.1M
-$11.74M
-$13.09M
-$11.92M
-$10.72M
-$15.59M
-$19.8M
-$35.94M
Income taxes
$612K
$6K
$288K
-$9.3M
$424K
$1M
$914K
-$1.41M
Net income
-$10.71M
-$11.75M
-$13.38M
-$2.62M
-$11.15M
-$16.59M
-$20.71M
-$34.53M
Net income attributable to common shareholders
-$10.71M
-$11.75M
-$13.38M
-$2.62M
-$11.15M
-$16.59M
-$20.71M
-$34.53M
EBITDA
-$187K
-$1.87M
-$4.03M
-$1.45M
-$1.64M
-$11.75M
-$14.61M
-$16.52M
Basic earnings per share
-$0.35
-$0.39
-$0.45
-$0.09
-$0.38
-$0.57
-$0.70
-$1.20
Diluted earnings per share
-$0.35
-$0.39
-$0.45
-$0.09
-$0.38
-$0.57
-$0.70
-$1.20
Recent news
Company coverage with links to the original publishers.
Establishment Labs reported a Q3 loss of $0.35 per share, missing EPS expectations by 29.63%, though it beat revenue estimates with $71.99 million (8.03% above consensus). The company has underperformed the S&P 500 by 18.5% year-to-date. With a Zacks Rank #3 (Hold) rating and the Medical Services industry in the bottom 40% of performance, the stock is expected to perform in line with the market.
Establishment Labs (ESTA) is expected to report a quarterly loss of $0.27 per share with revenues of $66.64 million, up 23.9% year-over-year. The company has a positive Earnings ESP of +20.76% combined with a Zacks Rank #3, suggesting it will likely beat consensus EPS estimates. However, the company has a mixed earnings surprise history, beating estimates only twice in the last four quarters.
Hedge fund JW Asset Management sold 90,533 shares of Establishment Labs (ESTA) between May 26-28, 2026, generating approximately $6.64 million at a weighted average price of $73.31 per share. The sale reduced the fund's ownership below the 10% threshold, though it retained nearly 3 million shares, suggesting continued bullish sentiment. The timing coincided with strong company performance, including 45% year-over-year revenue growth and inclusion in the Russell 2000 Index.
Establishment Labs founder Juan José Chacón Quirós sold 105,000 shares worth $7.9 million on May 6, 2026, but the timing coincided with earnings day due to a pre-scheduled 10b5-1 plan adopted in December 2025. The real story is the company's strong Q1 performance: US revenue grew 13.3% to $19.6 million, the company posted its third consecutive quarter of positive adjusted EBITDA, and management raised full-year guidance while targeting free cash flow positive in H2 2026.
The global breast implants market is projected to grow from USD 2.93 billion in 2025 to USD 5.62 billion by 2034, driven by rising breast cancer cases and aesthetic surgery demand, with North America leading market share and Asia Pacific expected to witness fastest growth.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.